Follow Tempus AI to never miss an important update.
Tempus received 510(k) clearance, which is the FDA's way of approving a medical device as safe and effective, for a tool that analyzes standard heart tests to find mitral regurgitation. This is a condition where blood leaks backward through a heart valve. It is often hard to catch because patients may not show symptoms in the early stages.
This is a win for the company because it expands its reach beyond cancer care into heart health. By turning a routine test into a screening tool for a specific disease, Tempus makes its platform more useful to a wider range of doctors. This helps the company gather more data, which is the core asset it sells to drug companies for research.
Source: Business Wire
Tempus AI and its consulting arm expanded a distribution deal with TempraMed. The updated agreement moves beyond Panama into additional Latin American markets and includes VIVI Med, a product used to manage temperature-sensitive medications. While the financial details were not shared, the move helps Tempus grow its footprint in a region where it is working to register more products for sale.
Goldman Sachs set a $75 price target for Tempus AI this week. This is a bit higher than the $70 average target from other analysts who follow the stock. Because the stock is currently trading above $83, this suggests the firm sees the business as fairly valued or slightly ahead of itself after its recent rise.
Source: Goldman Sachs
Tempus AI has extended its data licensing agreement with Recursion Pharmaceuticals for an additional five years. Under the deal, the two companies will share medical data and Tempus will gain access to Recursion's foundation models, which are AI systems trained on vast amounts of biological data to help predict how new drugs might work.
This extension is a positive sign for the company's data licensing business, which is its most profitable arm. By securing a long-term partner like Recursion, Tempus reinforces the value of its medical library as a necessary tool for biotech firms trying to speed up drug discovery. This steady licensing income is the primary path for the company to reach its goal of full profitability by 2027.
Source: Business Wire
Tempus AI is partnering with the drugmaker Merck to use artificial intelligence and genetic data to improve how treatments are developed. The partnership focuses on precision medicine, which is the practice of tailoring medical care to a patient's specific genetic makeup rather than using a one-size-fits-all approach.
This deal is a practical example of the company's main business goal: selling access to its massive library of medical records and genetic tests to big drug companies. These firms pay for this data because it helps them understand which patients will respond best to new drugs, which can speed up research and lower the cost of bringing a product to market.
Management has established a reliable habit of setting conservative targets and clearing them, having topped analyst expectations in seven of the last eight quarters.
| Expectation | |
|---|---|
| EPS | $-0.07 |
| Revenue | $410M |